Glycopyrronium Bromide Mercury Pharmaceuticals (Glycopyrronium Bromide)

Glycopyrronium bromide is primarily indicated for the management of primary hyperhidrosis, a condition characterized by excessive sweating.

• Treatment of focal hyperhidrosis of the palms, soles, or axillae when applied via iontophoresis.
• Adjunct therapy for secondary hyperhidrosis associated with neurological disorders.
• Consideration as an alternative to topical antiperspirants in patients unresponsive to conventional measures.
• Use in clinical settings where localized reduction of sweat production is desired.
• Part of a comprehensive sweat management program that may include behavioral strategies and skin care.

The safety profile of glycopyrronium bromide administered by iontophoresis includes both frequent mild reactions and rare but serious events.

Common

• Transient skin irritation or erythema at the application site.
• Mild tingling or pruritus during treatment.
• Temporary dryness of the treated area.
• Slight reduction in local sweating that resolves after discontinuation.

Serious

• Severe allergic reaction such as urticaria, angioedema, or anaphylaxis.
• Persistent dysuria or urinary retention.
• Significant cardiovascular effects like tachycardia or arrhythmia.

When using glycopyrridium bromide via iontophoresis, clinicians should observe several precautionary measures to ensure patient safety.

• Assess for known hypersensitivity to anticholinergic agents before initiating therapy.
• Use caution in patients with glaucoma, urinary retention, or gastrointestinal obstruction.
• Avoid application on broken or infected skin.
• Monitor cardiovascular status in individuals with pre‑existing heart conditions.
• Limit session duration and frequency according to manufacturer guidelines.
• Educate patients on proper electrode placement and skin preparation.

Glycopyrronium bromide may interact with other medications that influence cholinergic or cardiac function.

Avoid

• Concurrent use with other anticholinergic drugs (e.g., atropine, scopolamine) may increase anticholinergic burden.
• Co‑administration with beta‑blockers or calcium‑channel blockers in patients prone to bradycardia.

Use with caution

• Combined therapy with drugs that affect QT interval (e.g., certain antiarrhythmics) should be monitored.
• Use alongside medications that cause dry mouth or constipation may exacerbate these effects.
• Patients on systemic anticholinergics should have dosage adjustments considered.